In this article, Andrew Tepperman discusses a set of specific liability and damages issues that could be addressed by economic and business expert testimony. The context is assumed to be an international arbitration proceeding involving firms in the pharmaceutical industry. This article appeared in the 2015 edition of The International Comparative Legal Guide to: International Arbitration, published by Global Legal Group Ltd, London. To read the article, click the link below.
Significant tax risk to non-US companies created by America First Trade Policy
On his first day in office, President Trump signed two memoranda, the Global Tax Deal and the America First Trade Policy, covering noteworthy international...